https://unauthorised investment advice/health/creso-pharmas-subsidiary-halucenexs-key-psychedelic-ingredient-passes-crucial-testing-and-is-one-step-closer-to-phase-two-clinical-trials/
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
